{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T07:01:31Z","timestamp":1775804491270,"version":"3.50.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atopic dermatitis (AD) is a clinically heterogeneous immune-mediated skin disorder. The lack of reliable clinical stratification tools and predictive biomarkers for therapeutic response remains a critical unmet need to optimize treatment and advance precision dermatology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the association between genetic variants and AD phenotypes and response to Dupilumab as a potential approach to individualize therapy in moderate-to-severe AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>120 patients with moderate-to-severe AD treated with Dupilumab were enrolled at two Italian centers. Clinical data, including phenotypes, severity, and comorbidities, were collected at baseline and after 48 weeks treatment with Dupilumab. Its efficacy was assessed as EASI75 and EASI90 achievements at week 48. Genotyping of 521 SNPs was performed using next-generation sequencing (NGS). Cluster analysis and univariate logistic regression explored associations between genetic profiles and clinical variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      NGS-based genotyping enabled the stratification of patients into four distinct genetic clusters, each characterized by unique combinations of polymorphisms in skin barrier\u2013related genes, namely\n                      <jats:italic>FLG<\/jats:italic>\n                      and\n                      <jats:italic>KIF3A<\/jats:italic>\n                      . Specific SNPs in additional barrier-related genes (RPTN rs3001978, TH2LCRR rs2158177 and rs3091307) and Th2 pathway genes (IL4R rs1805016, STAT6 rs324011) were differentially distributed across the clusters. A combined variant pattern in\n                      <jats:italic>KIF3A<\/jats:italic>\n                      and\n                      <jats:italic>FLG<\/jats:italic>\n                      was strongly associated with a generalized eczema phenotype. Some allelic variants of genes were found to be associated with conjunctivitis (\n                      <jats:italic>FLG<\/jats:italic>\n                      ), rhinitis (\n                      <jats:italic>KIF3A<\/jats:italic>\n                      ), bronchial asthma (\n                      <jats:italic>IL5RA<\/jats:italic>\n                      ) comorbidities and high IgE levels (\n                      <jats:italic>ADAM33<\/jats:italic>\n                      ). Notably, FLG rs749682384 and IL6R rs2228145 variants emerged as predictors of favorable response to Dupilumab, while RPTN rs3001978 and TSLP rs2289276 variants were associated with a therapy failure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study identified genetic signatures in skin barrier and Th2 pathway genes associated with clinical phenotypes and differential responses to Dupilumab in AD. Findings support incorporating genotypic profiling into practice to guide personalized therapy in moderate-to-severe AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1788831","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:06:24Z","timestamp":1775801184000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetic profiling of patients with atopic dermatitis reveals immune and skin barrier variants associated with generalized eczema and optimal response to Dupilumab therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Martina","family":"Morelli","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Immunology Unit, IDI-IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Luca","family":"Scaglione","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Immunology Unit, IDI-IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Dattolo","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Immunology Unit, IDI-IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Galluzzo","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d","place":["Rome, Italy"]},{"name":"Dermatology Unit, Fondazione Policlinico \u201cTor Vergata\u201d","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Scarponi","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Immunology Unit, IDI-IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaia","family":"Moretta","sequence":"additional","affiliation":[{"name":"Department of Dermatology Unit, Istituto Dermopatico dell\u2019Immacolata - Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS)","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Provini","sequence":"additional","affiliation":[{"name":"Department of Dermatology Unit, Istituto Dermopatico dell\u2019Immacolata - Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS)","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filomena","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Dermatology Unit, Istituto Dermopatico dell\u2019Immacolata - Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS)","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Cocuroccia","sequence":"additional","affiliation":[{"name":"Department of Dermatology Unit, Istituto Dermopatico dell\u2019Immacolata - Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS)","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella","family":"Sordi","sequence":"additional","affiliation":[{"name":"Department of Dermatology Unit, Istituto Dermopatico dell\u2019Immacolata - Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS)","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Talamonti","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione Policlinico \u201cTor Vergata\u201d","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Villella","sequence":"additional","affiliation":[{"name":"Molecular Allergology Unit, IDI-IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio Romano","family":"Selvi","sequence":"additional","affiliation":[{"name":"Department of Dermatology Unit, Istituto Dermopatico dell\u2019Immacolata - Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS)","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mercurio","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Immunology Unit, IDI-IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Paganini","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Mortato","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d","place":["Rome, Italy"]},{"name":"Dermatology Unit, Fondazione Policlinico \u201cTor Vergata\u201d","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ornella","family":"De Pit\u00e0","sequence":"additional","affiliation":[{"name":"Department of Dermatology Unit, Istituto Dermopatico dell\u2019Immacolata - Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS)","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabatino","family":"Pallotta","sequence":"additional","affiliation":[{"name":"Department of Dermatology Unit, Istituto Dermopatico dell\u2019Immacolata - Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS)","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Scala","sequence":"additional","affiliation":[{"name":"Molecular Allergology Unit, IDI-IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Albanesi","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Immunology Unit, IDI-IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Madonna","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Immunology Unit, IDI-IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02519-4","article-title":"Atopic dermatitis","volume":"405","author":"Guttman-Yassky","year":"2025","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaci.2025.02.029","article-title":"Endotypes of atopic dermatitis","volume":"156","author":"Fyhrquist","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/all.16377","article-title":"A microarray-based IgE-molecular mimicry index (IgE-MMI): A biomarker for disease severity, clinical phenotypes, and therapeutic response in atopic dermatitis","volume":"79","author":"Scala","year":"2024","journal-title":"Allergy"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052684","article-title":"Multiple roles for cytokines in atopic dermatitis: From pathogenic mediators to endotype-specific biomarkers to therapeutic targets","volume":"23","author":"Fania","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1038\/s41467-020-17895-x","article-title":"Disease-associated KIF3A variants alter gene methylation and expression impacting skin barrier and atopic dermatitis risk","volume":"11","author":"Stevens","year":"2020","journal-title":"Nat Commun"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3424","article-title":"Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis","volume":"47","author":"Paternoster","year":"2015","journal-title":"Nat Genet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/ng.1017","article-title":"Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis","volume":"44","author":"Paternoster","year":"2012","journal-title":"Nat Genet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddt317","article-title":"A genome-wide association study of atopic dermatitis identifies loci with overlapping effects on asthma and psoriasis","volume":"22","author":"Weidinger","year":"2013","journal-title":"Hum Mol Genet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2642","article-title":"High-density genotyping study identifies four new susceptibility loci for atopic dermatitis","volume":"45","author":"Ellinghaus","year":"2013","journal-title":"Nat Genet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1038\/s41467-023-41180-2","article-title":"European and multi-ancestry genome-wide association meta-analysis of atopic dermatitis highlights importance of systemic immune regulation","volume":"14","author":"Budu-Aggrey","year":"2023","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01453-8","article-title":"Real-world effectiveness and safety of dupilumab, tralokinumab, and upadacitinib in patients with atopic dermatitis: A 52-week international, multicenter retrospective cohort study","volume":"15","author":"Torres","year":"2025","journal-title":"Dermatol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: A randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.02.036","article-title":"Identifying atopic dermatitis risk loci in 1,094,060 individuals with subanalysis of disease severity and onset","volume":"144","author":"Pasanen","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1862082","article-title":"HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis","volume":"21","author":"Morelli","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12178","article-title":"Association of KIF3A, but not OVOL1 and ACTL9, with atopic eczema in Italian patients","volume":"168","author":"Lepre","year":"2013","journal-title":"Br J Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2024.148397","article-title":"Association between polymorphisms and atopic dermatitis susceptibility: A systematic review and meta-analysis","volume":"913","author":"Huang","year":"2024","journal-title":"Gene"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.393","article-title":"One remarkable molecule: Filaggrin","volume":"132","author":"Brown","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/ng1767","article-title":"Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis","volume":"38","author":"Palmer","year":"2006","journal-title":"Nat Genet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15130","article-title":"Increased loss-of-function filaggrin gene mutation prevalence in atopic dermatitis patients across northern latitudes indicates genetic fitness: A systematic review and meta-analysis","volume":"33","author":"Khatib","year":"2024","journal-title":"Exp Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105318","article-title":"Revisiting the roles of filaggrin in atopic dermatitis","volume":"23","author":"Moosbrugger-Martinz","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40521-020-00271-x","article-title":"Filaggrin gene mutations with special reference to atopic dermatitis","volume":"7","author":"Gupta","year":"2020","journal-title":"Curr Treat Options Allergy"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1159\/000109365","article-title":"R501X and 2282del4 filaggrin mutations do not confer susceptibility to psoriasis and atopic dermatitis in Italian patients","volume":"216","author":"Giardina","year":"2007","journal-title":"Dermatology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04073.x","article-title":"Individuals who are homozygous for the 2282del4 and R501X filaggrin null mutations do not always develop dermatitis and complete long-term remission is possible","volume":"26","author":"Thyssen","year":"2012","journal-title":"J Eur Acad Dermatol Venereology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.03.036","article-title":"Meta-analysis of filaggrin polymorphisms in eczema and asthma: Robust risk factors in atopic disease","volume":"123","author":"Rodr\u00edguez","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.12816\/0031218","article-title":"Molecular genetic of atopic dermatitis: An update","volume":"10","author":"Al-Shobaili","year":"2016","journal-title":"Int J Health Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s00403-024-03273-w","article-title":"Novel loss-of-function variants in filaggrin exon 3 in patients with severe atopic dermatitis","volume":"316","author":"Bellinato","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/15257770.2021.1880009","article-title":"Missense, silent, non-sense and frame-shift mutations in exon 3 of the filaggrin gene in patients with bronchial asthma, atopic dermatitis, allergic rhinitis and mixed atopy","volume":"40","author":"Salama","year":"2021","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2022.04.005","article-title":"Prevalence of filaggrin gene polymorphisms (exon-3) in patients with atopic dermatitis in a multiracial Brazilian population","volume":"98","author":"Laczynski","year":"2023","journal-title":"Bras Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.13.1.613-625.1993","article-title":"Profilaggrin is a major epidermal calcium-binding protein","volume":"13","author":"Markova","year":"1993","journal-title":"Mol Cell Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.05.030","article-title":"A role for the primary cilium in notch signaling and epidermal differentiation during skin development","volume":"145","author":"Ezratty","year":"2011","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1242\/dev.060210","article-title":"Role of epidermal primary cilia in the homeostasis of skin and hair follicles","volume":"138","author":"Croyle","year":"2011","journal-title":"Development"},{"key":"B34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ajpath.2020.09.007","article-title":"Novel functions of the septin cytoskeleton: Shaping up tissue inflammation and fibrosis","volume":"191","author":"Ivanov","year":"2021","journal-title":"Am J Pathol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nature00878","article-title":"Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness","volume":"418","author":"Van Eerdewegh","year":"2002","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2008.12.014","article-title":"ADAM33 genetic polymorphisms and risk of atopic dermatitis among Japanese children","volume":"42","author":"Matsusue","year":"2009","journal-title":"Clin Biochem"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.12.027","article-title":"Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis","volume":"153","author":"Clabbers","year":"2024","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1788831\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:06:25Z","timestamp":1775801185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1788831\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2026.1788831"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1788831","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"1788831"}}